4-(5-cyano-pyridin-2-yloxy)-piperidine-1-carboxylic acid tert-butyl ester | 194668-38-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(5-cyano-pyridin-2-yloxy)-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: t-butyl 4-[(5-cyanopyridin-2-yl)oxy]piperidine-1-carboxylate；tert-butyl 4-[(5-cyanopyridin-2-yl)oxy]piperidine-1-carboxylate；Tert-butyl 4-(5-cyanopyridin-2-yloxy)piperidine-1-carboxylate；tert-butyl 4-(5-cyanopyridin-2-yl)oxypiperidine-1-carboxylate
• CAS: 194668-38-7
• 化学式: C₁₆H₂₁N₃O₃
• 分子量: 303.361
• InChiKey: OUFLLMBRVSEWQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  75.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(5-cyano-pyridin-2-yloxy)-piperidine-1-carboxylic acid tert-butyl ester 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 生成 6-(piperidin-4-yl)oxypyridine-3-carbonitrile dihydrochloride
  参考文献：
  名称：

  EP2258697

  摘要：

  公开号：
• 作为产物：
  描述：

  t-butyl 4-((5-formylpyridin-2-yl)oxy)piperidine-1-carboxylate 在 吡啶 、 盐酸羟胺 作用下， 生成 4-(5-cyano-pyridin-2-yloxy)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  WO2007/1975

  摘要：

  公开号：

文献信息

• [EN] IMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLE
  申请人：INTERVET INT BV

  公开号：WO2012164071A1

  公开（公告）日：2012-12-06

  Described herein are compounds of formula (I), The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

  本文描述了式(I)的化合物。式(I)的化合物作为DGAT1抑制剂，可用于预防、治疗或作为高脂血症、糖尿病和肥胖的治疗药物。
• [EN] OPIOID RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RECEPTEUR OPIOIDE
  申请人：LILLY CO ELI

  公开号：WO2005061442A1

  公开（公告）日：2005-07-07

  A compound of the formula (I) wherein the variables X1 to X5, R1 to R7 including R3', E, q, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

  本文披露了式(I)的化合物，其中变量X1至X5、R1至R7包括R3'、E、q、v、y、z、A和B的含义如所述，或其药学上可接受的盐、溶剂合物、对映体、外消旋体、二对映体或其混合物，用于治疗、预防或改善肥胖症及相关疾病。
• Heterocyclic compounds useful as pharmaceutical agents
  申请人：Zeneca Limited

  公开号：US06313127B1

  公开（公告）日：2001-11-06

  Compounds of formula (I) in which all variables are defined in the description and their salts inhibit the enzyme oxido squalene cyclase and are useful in treating hypercholesterolemia and also as anti-fungal agents. Processes for their preparation are also described together with their use in medicine.

  式(I)的化合物，其中所有变量在描述中已定义，及其盐可以抑制酶氧化齐墩果烷环化酶，可用于治疗高胆固醇血症，也可用作抗真菌剂。本文还描述了它们的制备过程以及它们在医学中的应用。
• Opioid receptor antagonists
  申请人：Benesh Rae Dana

  公开号：US20070010558A1

  公开（公告）日：2007-01-11

  A compound of the formula (I) wherein the variables X 1 to X 5 , R 1 to R 7 including R 3′ , E, q, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

  本发明揭示了一种式子（I）的化合物，其中变量X1到X5、R1到R7包括R3'、E、q、v、y、z、A和B如所述，或其药学上可接受的盐、溶剂化物、对映体、消旋体、非对映体异构体或其混合物，用于治疗、预防或改善肥胖症及相关疾病。
• HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE
  申请人：Motoki Kayoko

  公开号：US20110053933A1

  公开（公告）日：2011-03-03

  The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: wherein, each of R 1 and R 2 independently represents a group such as a hydrogen atom or a halogen atom; R 3 represents a group such as a hydrogen atom; each of R 4 and R 5 independently represents a group such as a hydrogen atom, a halogen atom or a C 1-4 alkyl group; each of R 6 and R 7 independently represents a hydrogen atom or a C 1-4 alkyl group; X represents a group such as a C 3-10 cycloalkyl group, C 6-10 aryl group or a 5- to 10-membered heterocyclic group, which may be substituted with substituent(s) selected from substituent group α; Y represents a group such as —CO—, —O— or —NRa—, and Ra represents a group such as a hydrogen atom or a C 1-4 alkyl group.

  本发明提供了一种新型的羟基喹喔啉羧酰胺衍生物，可用于预防和/或治疗血液凝固障碍。该化合物由式(i)表示，或其药学上可接受的盐：其中，R1和R2各自独立地表示氢原子或卤素原子等基团；R3表示氢原子等基团；R4和R5各自独立地表示氢原子、卤素原子或C1-4烷基等基团；R6和R7各自独立地表示氢原子或C1-4烷基等基团；X表示C3-10环烷基、C6-10芳基或5-至10元杂环基等基团，该基团可以被选自取代基团α的取代基团所取代；Y表示—CO—、—O—或—NRa—等基团，其中Ra表示氢原子或C1-4烷基等基团。